Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors replyShow others and affiliations
2021 (English)In: Alimentary Pharmacology and Therapeutics, ISSN 0269-2813, E-ISSN 1365-2036, Vol. 54, no 6, p. 848-849Article in journal, Editorial material (Other academic) Published
Place, publisher, year, edition, pages
Chichester, United Kingdom: Wiley-Blackwell , 2021. Vol. 54, no 6, p. 848-849
National Category
Rheumatology and Autoimmunity Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:liu:diva-185164DOI: 10.1111/apt.16569ISI: 000687344700012PubMedID: 34425010Scopus ID: 2-s2.0-85113232372OAI: oai:DiVA.org:liu-185164DiVA, id: diva2:1659035
2022-05-182022-05-182022-06-14Bibliographically approved